JAK/TYK2

      POS0150: From 12 RA registries, JAKi starts fell by ~13% after FDA safety alerts.
      Tofa & bari took biggest hits; upa

      Jiha Lee JihaRheum

      4 months 2 weeks ago
      POS0150: From 12 RA registries, JAKi starts fell by ~13% after FDA safety alerts. Tofa & bari took biggest hits; upa growth slowed but offset losses. Real-world prescribing adapts—but doesn’t abandon. @RheumNow #EULAR2025 https://t.co/QZ5haW2vhX
      Fascinating to see JAKi uptake in European JAK-pot centres
      - tofa was already on the decline pre-ORAL Surveillance
      - JAK

      David Liew drdavidliew

      4 months 2 weeks ago
      Fascinating to see JAKi uptake in European JAK-pot centres - tofa was already on the decline pre-ORAL Surveillance - JAKi use (driven by upadacitinib) continues to grow, although maybe it’s slowed Hopefully rational JAKi has its place #EULAR2025 POS0150 @RheumNow https://t.co/XRyHJVw821
      New dual-action RA drug?
      OP0193: CPL’116 targets both JAK & ROCK.
      In 12-wk RCT, highest dose improved DAS28-CRP,

      Jiha Lee JihaRheum

      4 months 2 weeks ago
      New dual-action RA drug? OP0193: CPL’116 targets both JAK & ROCK. In 12-wk RCT, highest dose improved DAS28-CRP, joint counts & pain, with clean labs. Is this a future option for RA-ILD or patients with comorbid CVD risk? #EULAR2025 @RheumNow
      Ph 2 RCT CPL'116 dual inhibition JAK/ROCK
      106 MTX IR pts
      wk12 primary endpoint met (DAS28-CRP decrease) in 240mg arm vs.

      Aurelie Najm AurelieRheumo

      4 months 2 weeks ago
      Ph 2 RCT CPL'116 dual inhibition JAK/ROCK 106 MTX IR pts wk12 primary endpoint met (DAS28-CRP decrease) in 240mg arm vs. PBO 75% >= AEs, SAE 2: 1 MI, 1 bladder cancer Authors suggest absence of lipids/LFTs disruption compared to other JAKs Ph3 is awaited!! #OP0193 #EULAR2025 https://t.co/TnnM410LfM
      Real-world study on dual bDMARD plus JAKi or TYK2i combinations in refractory PsA. 22 PsA patients on dual bDMARD + JAK

      Antoni Chan MD (Prof) synovialjoints

      4 months 2 weeks ago
      Real-world study on dual bDMARD plus JAKi or TYK2i combinations in refractory PsA. 22 PsA patients on dual bDMARD + JAKi/TYK2i: •Most common: IL-17i + TYK2i •Total exposure: 8.5–10.5 pt-years •Only mild URIs/stomatitis •Clinical improvements seen in joint/skin domains https://t.co/waDReDqSDE
      Hepcidin detected in synovial membrane and fluid in RA, PsA, and OA. Monocytes were the main source. IL-6, IL-10, IL-17,

      Antoni Chan MD (Prof) synovialjoints

      4 months 2 weeks ago
      Hepcidin detected in synovial membrane and fluid in RA, PsA, and OA. Monocytes were the main source. IL-6, IL-10, IL-17, M-CSF induced hepcidin via JAK-STAT pathway. Hepcidin reduced osteoclastogenesis but correlated with synovial neutrophils and CXCL1 induction. Functional dual https://t.co/ZjUtTYPre8
      Phase 3 of POETYK-PsA-2:
      -Deucravacitinib (oral TyK2i) met the primary endpoint of ACR20 at week 16 and was superior to

      Adela Castro AdelaCastro222

      4 months 2 weeks ago
      Phase 3 of POETYK-PsA-2: -Deucravacitinib (oral TyK2i) met the primary endpoint of ACR20 at week 16 and was superior to placebo in multiple PsA domains. -Clinical efficacy maintained until week 52. -No major safety signals reported. -Notably high placebo response rates. Abstract
      PSA2L.jpg
      Combination treatments in Psoriatic Arthritis
      4 months 2 weeks ago
      Despite the advances in the treatment of PsA with biologic (bDMARD) and targeted synthetic (tsDMARD), less than half of patients with this condition achieved remission or low disease activity. Combination DMARD treatment is often used in order to achieve remission or minimal disease activity. The standard practice is to use a conventional synthetic (csDMARD) with a bDMARD. The use of the combination of bDMARD with a tsDMARD such as a JAKi or
      ❓️How effective and safe is it to combine bDMARDs and tsDMARDS (i.e. TNFi/ IL17i + JAKi/TYKi) in #psoriatic_arthrit

      Nelly ZIADE 🍀 Nellziade

      4 months 2 weeks ago
      ❓️How effective and safe is it to combine bDMARDs and tsDMARDS (i.e. TNFi/ IL17i + JAKi/TYKi) in #psoriatic_arthritis? 🅰️ Reassuring data from a case-series study presented by Andre Lucas Ribeiro #EULAR2025 OP0090 @RheumNow #Strategy https://t.co/W8fuzSgxbJ
      Efficacy and safety of deucravacitinib up to week 52 in the POETYK PsA-2 study
      •ACR20 at W16: 54.2% (deucravacitinib)

      Antoni Chan MD (Prof) synovialjoints

      4 months 2 weeks ago
      Efficacy and safety of deucravacitinib up to week 52 in the POETYK PsA-2 study •ACR20 at W16: 54.2% (deucravacitinib) vs 39.4% (placebo), p=0.0002 •PASI75: 40.9% vs 15.4%, p<0.0001 •MDA: 25.6% vs 14.7%, p=0.0007 •FACIT-F: +2.5 vs +1.8 •SAE: 1.9% (low) TYK2 inhibition shows https://t.co/JXTZRk2itA
      Comparative efficacy of tofacitinib vs. adalimumab in RA - metanalysis of 9 RCTs, 24,643 pts finds Tofa signif superior

      Dr. John Cush RheumNow

      4 months 2 weeks ago
      Comparative efficacy of tofacitinib vs. adalimumab in RA - metanalysis of 9 RCTs, 24,643 pts finds Tofa signif superior to ADA for ACR20 (RR 1.28), HAQ-DI, VAS, but no difference in adverse events (RR 0.96) or DAS28-CRP improvement https://t.co/5mVY2Qvdms https://t.co/czxnlYHEAl
      Ph 2 open label RCT TOFA in RA-ILD 52 wks
      39pts 92% AE 8% 3 deaths FVC decline -69 ml
      No diff between UIP, NSIP or antif

      Aurelie Najm AurelieRheumo

      4 months 2 weeks ago
      Ph 2 open label RCT TOFA in RA-ILD 52 wks 39pts 92% AE 8% 3 deaths FVC decline -69 ml No diff between UIP, NSIP or antifibrotic No control group #POS0619 #EULAR2025 @RheumNow https://t.co/3lqEUfObG9
      What’s worse for infection in GCA: tail end steroid taper, or a JAK inhibitor?

      This is exactly SELECT-GCA in the seco

      David Liew drdavidliew

      4 months 2 weeks ago
      What’s worse for infection in GCA: tail end steroid taper, or a JAK inhibitor? This is exactly SELECT-GCA in the second 6mo. What happened? upa skews better on serious infection, worse on HZ JAKi might have infection risk, but not like steroids. OP0057 #EULAR2025 @RheumNow https://t.co/FigxviOW3e
      Case series of 22 PsA pts treats w/ combination bioDMARDs & JAKi,TYK2i or APR
      IL17i + JAKi 10.5 PY = 1 mild infectio

      Aurelie Najm AurelieRheumo

      4 months 2 weeks ago
      Case series of 22 PsA pts treats w/ combination bioDMARDs & JAKi,TYK2i or APR IL17i + JAKi 10.5 PY = 1 mild infectious stomatitis IL23i + JAKi 3.7 PY = no AE IL-17i + TYK2i 8.5 PY = 2 mild upper respiratory infections IL-23i + TYK2i 8.3 PY = 2 mild URIs, 1 folliculitis TNFi + https://t.co/Qg9HIwuslJ
      Worried about cancer risk with ts/bDMARDs in RA?

      Real-world data from over 4,600 patients says: don’t be. No increase

      Jiha Lee JihaRheum

      4 months 2 weeks ago
      Worried about cancer risk with ts/bDMARDs in RA? Real-world data from over 4,600 patients says: don’t be. No increased risk of cancer (incl. NMSC) for JAKi, IL6i, CD20i, or CTLA4-A vs TNFi in long-term registry follow-up. Abstract#OP0065 @RheumNow #EULAR2025

      Catch up on Conference Podcasts

      ×